Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +15

Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity - Quiver Quantitative

AI-generated analysis

πŸ“Š Gilead Sciences reported Q1 2026 revenues of $7 billion, marking a 4.39% increase from the prior year.

πŸ“‰ CEO Daniel Patrick O'Day sold 296,280 shares for an estimated $41.7 million in the last six months with zero purchases.

πŸ“ˆ Representative Jared Moskowitz purchased up to $30,000 of GILD stock on May 6, coinciding with other congressional buys.

🏦 FMR LLC added 6.3 million shares (+9.6%) worth ~$871 million in Q1 2026, while BlackRock removed 4.2 million shares (-3.4%).

πŸ“‰ Barclays PLC reduced its Gilead position by 42.1% (approx. $528 million) and Bank of America cut holdings by 13.6%.

🎯 Wall Street analysts maintain a median price target of $165, with Needham issuing a 'Buy' rating on February 11, 2026.

πŸ’Š Gilead is advancing STAT6 inhibitor programs for oral inflammation therapies, with data readouts anticipated in mid-2027.

πŸ“… Analyst price targets range widely from $122 (RBC Capital) to $180 (Jefferies), reflecting varied valuation expectations.

Bullish Signals
  • Gilead Sciences achieved a 4.39% year-over-year revenue increase in Q1 2026, reaching $7 billion.
  • Major institutional investor FMR LLC increased its GILD position by 9.6%, adding approximately $871 million to its portfolio.
  • Needham issued a 'Buy' rating on Gilead Sciences, contributing to a positive analyst consensus with a median target of $165.
  • The company is successfully advancing its pipeline with new licensing deals for STAT6 inhibitor programs in inflammation research.
Risk Factors
  • Significant institutional selling pressure was observed, with BlackRock reducing holdings by 3.4% and Barclays cutting its position by 42.1%.
  • Company insiders, including CEO Daniel Patrick O'Day and CFO Andrew D Dickinson, executed only sales totaling over $44 million in the last six months.
  • Multiple large institutional investors, including Bank of America and Wellington Management, reduced their Gilead positions significantly in Q1 2026.
Full Analysis
Gilead Sciences (GILD) recently saw a mix of insider trading activity, with company executives selling shares while members of Congress made purchases. CEO Daniel Patrick O'Day sold 296,280 shares for approximately $41.7 million over the last six months, whereas Representative Jared Moskowitz purchased up to $30,000 in May. This divergence highlights contrasting perspectives on the stock's near-term outlook between management and external investors. Institutional investor sentiment remains mixed but shows significant capital rotation. Major asset managers like FMR LLC increased their holdings by 9.6% (adding roughly $871 million), while BlackRock, Barclays, and Bank of America reduced positions significantly, with Barclays cutting its stake by over 42%. Despite these large outflows from some giants, the net institutional activity reflects a complex rebalancing rather than a uniform sell-off. Analyst consensus remains cautiously positive with a median price target of $165. Needham recently issued a 'Buy' rating, and targets range from $122 to $180 across major firms like Citigroup and Morgan Stanley. Financially, Gilead reported Q1 2026 revenues of $7 billion, representing a 4.39% year-over-year increase, indicating stable top-line growth despite the volatility in ownership structures. The company is also advancing its pipeline with new licensing deals for STAT6 inhibitor programs aimed at oral therapies for inflammation. These strategic moves position Gilead against peers like Johnson & Johnson, with data readouts expected around mid-2027. While insider selling and institutional reductions present some cautionary signals, the revenue growth and analyst support suggest a balanced market view.